Kabi Commits To Biosimilars Development

 
• By Aidan Fry

Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.

Kabil
Attendees of the official inauguration of Fresenius Kabi's biosimilars research and development center in Eysins, Switzerland, included the company's CEO, Mats Henriksson (third left) • Source: Fresenius Kabi

More from Biosimilars

More from Products